RESUMEN
BACKGROUND: The promotion of the latest medicines produced by the pharmaceutical industry is an important issue both from an ethical point of view (the level of accessibility, the way research is carried out) and from the point of view of marketing and especially from the lobbying issues raised. AREAS OF UNCERTAINTY: The ethical dilemmas raised by the promotion of new drugs revolve between the need to discover new molecules important for treating a wide range of diseases and the need to establish a battery of ethical rules, absolutely necessary for regulations in the field to be compliant with all ethical principles. DATA SOURCES: A literature search was conducted through PubMed, MEDLINE, Plus, Scopus, and Web of Science (2015-2023) using combinations of keywords, including drugs, medical publicity, and pharma marketing plus ethical dilemma. ETHICS AND THERAPEUTIC ADVANCES: The promotion of medicines is governed by advertising laws and regulations in many countries, including at EU level, based on the need for countries to ensure that the promotion and advertising of medicines is truthful, based on information understood by consumers. The ethical analysis of the issues raised is more necessary and complex as the channels used for promotion are more accessible to the population, and the information, easier to obtain, can be the cause of increased self-medication and overeating. Large amounts of money invested in the development of new molecules, but also the risk of scientific fraud through manipulation of data during clinical trials, selective or biased publication of information can have repercussions on the health of the population. CONCLUSIONS: The development of new pharmaceutical molecules is necessary to intervene and treat as many conditions as possible, but marketing must not neglect the observance of ethical principles. The promotion of medicines should be the attribute especially of the medical staff, which should also be a mandatory part of the mechanism for approving the marketing methods and means used by the pharmaceutical companies.
Asunto(s)
Industria Farmacéutica , Humanos , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/economía , Industria Farmacéutica/ética , Publicidad/ética , Publicidad/legislación & jurisprudencia , Publicidad/economía , Mercadotecnía/legislación & jurisprudencia , Mercadotecnía/ética , Mercadotecnía/economía , Conflicto de Intereses/economíaRESUMEN
This study evaluates adherence to industry and professional standards among physicians endorsing drugs and devices on a social media platform.
Asunto(s)
Industria Farmacéutica , Médicos , Medios de Comunicación Sociales , Humanos , Conflicto de Intereses , Revelación , Industria Farmacéutica/economía , Industria Farmacéutica/ética , Equipos y Suministros/economía , Médicos/economía , Médicos/ética , Medios de Comunicación Sociales/economía , Medios de Comunicación Sociales/ética , Estados Unidos , Mercadotecnía/economía , Mercadotecnía/ética , Estudios Transversales , Profesionalismo/economía , Profesionalismo/ética , Profesionalismo/normasRESUMEN
Importance: Sponsorship of promotional events for health professionals is a key facet of marketing campaigns for pharmaceuticals and medical devices; however, there appears to be limited transparency regarding the scope and scale of this spending. Objective: To develop a novel method for describing the scope and quantifying the spending by US pharmaceutical and medical companies on industry-sponsored promotional events for particular products. Design and Setting: This was a cross-sectional study using records from the Centers for Medicare & Medicaid's Open Payments database on payments made to prescribing clinicians from January 1 to December 21, 2022. Main Outcomes and Measures: An event-centric approach was used to define sponsored events as groupings of payment records with matching variables. Events were characterized by value (coffee, lunch, dinner, or banquet) and number of attendees (small vs large). To test the method, the number of and total spending for each type of event across professional groups were calculated and used to identify the top 10 products related to dinner events. To validate the method, we extracted all event details advertised on the websites of 4 state-level nurse practitioner associations that regularly hosted industry-sponsored dinner events during 2022 and compared these with events identified in the Open Payments database. Results: A total of 1â¯154â¯806 events sponsored by pharmaceutical and medical device companies were identified for 2022. Of these, 1â¯151â¯351 (99.7%) had fewer than 20 attendees, and 922â¯214 (80.0%) were considered to be a lunch ($10-$30 per person). Seven companies sponsored 16â¯031 dinners for the top 10 products. Of the 227 sponsored in-person dinner events hosted by the 4 state-level nurse practitioner associations, 168 (74.0%) matched events constructed from the Open Payments dataset. Conclusions and Relevance: These findings indicate that an event-centric analysis of Open Payments data is a valid method to understand the scope and quantify spending by pharmaceutical and medical device companies on industry-sponsored promotional events attended by prescribers. Expanding and enforcing the reporting requirements to cover all payments to all registered health professionals would improve the accuracy of estimates of the true extent of all sponsored events and their impact on clinical practice.
Asunto(s)
Industria Farmacéutica , Humanos , Estudios Transversales , Estados Unidos , Industria Farmacéutica/economía , Mercadotecnía/economía , Conflicto de Intereses/economía , Centers for Medicare and Medicaid Services, U.S.RESUMEN
We investigate the hierarchical structure of Dhaka stocks' financial networks, known as an emerging market, from 2008 to 2020. To do so, we determine correlations from the returns of the firms over a one-year time window. Then, we construct a minimum spanning tree (MST) from correlations and calculate the hierarchy of the tree using the hierarchical path. We find that during the unprecedented crisis in 2010-11, the hierarchy of this emerging market did not sharply increase like in developed markets, implying the absence of a compact cluster in the center of the tree. Noticeably, the hierarchy fell before the big crashes in the Bangladeshi local market, and the lowest value was found in 2010, just before the 2011 Bangladesh market scam. We also observe a lower hierarchical MST during COVID-19, which implies that the network is fragile and vulnerable to financial crises not seen in developed markets. Moreover, the volatility in the topological indicators of the MST indicates that the network is adequately responding to crises and that the firms that play an important role in the market during our analysis periods are financial, particularly the insurance companies. We notice that the largest degrees are minimal compared to the total number of nodes in the tree, implying that the network nodes are somewhat locally compact rather than globally centrally coupled. For this random structure of the emerging market, the network properties do not properly reflect the hierarchy, especially during crises. Identifying hierarchies, topological indicators, and significant firms will be useful for understanding the movement of an emerging market like Dhaka Stock exchange (DSE), which will be useful for policymakers to develop the market.
Asunto(s)
COVID-19 , Inversiones en Salud , Bangladesh , COVID-19/epidemiología , COVID-19/economía , Humanos , Inversiones en Salud/economía , Comercio/economía , Administración Financiera , Modelos Económicos , SARS-CoV-2 , Mercadotecnía/economíaRESUMEN
No disponible
Asunto(s)
Femenino , Humanos , Masculino , Industria Farmacéutica/economía , Industria Farmacéutica/ética , Mercadotecnía/economía , Informe de Investigación/legislación & jurisprudencia , Trastornos Mentales/patología , Trastornos Mentales/psicología , Indicadores de Calidad de la Atención de Salud/legislación & jurisprudencia , Industria Farmacéutica/historia , Industria Farmacéutica/legislación & jurisprudencia , Mercadotecnía/organización & administración , Informe de Investigación/normas , Trastornos Mentales/complicaciones , Trastornos Mentales/diagnóstico , Indicadores de Calidad de la Atención de Salud/estadística & datos numéricos , Bibliografía de MedicinaRESUMEN
Este artigo trata do entretenimento como mercadoria valorizada pela sociedade regida pelo capital, pela capacidade que apresenta de incluir a todos, de diferentes idades e gêneros, diferentes estratos sociais, lugares e regiões e, portanto, ser uma fonte geradora de bens econômicos e simbólicos. Busca situar o entretenimento mundialmente, como um componente da cultura do tempo livre, com o poder de absorver pensamentos, corporeidades e estruturar a temporalidade das pessoas.
The present paper is related to entertainment as merchandise valued by a society ruled by the capitalism, because of this ability of including everyone, of different ages and gender, different social position, places and regions and, therefore, to be a generating source of economic and symbolic goods. It also has as objective to situate the entertainment globally, as a component of the spare time culture, with the power to absorb thoughts, body languages and to structure peoples temporariness.
El presente artículo se relaciona a la función del entretenimiento como mercancía valorada por una sociedad gobernada por el capitalismo, debido a esta habilidad de incluir a todos, de edades diferentes y género, posición social diferente, lugares y regiones y, por consiguiente, para ser una fuente generadora de género económico y simbólico. También tiene como el objetivo situar la función globalmente, como un componente de la cultura de tiempo libre, con el poder para absorber los pensamientos, corporalidades y para estructurar la temporalidad de las personas.
Asunto(s)
Humanos , Mercadotecnía/economía , Mercadotecnía/instrumentación , Mercadotecnía/métodos , Mercadotecnía , Mercadotecnía/tendencias , Medios de Comunicación de Masas/economía , Medios de Comunicación de Masas/ética , Medios de Comunicación de Masas/historia , Medios de Comunicación de Masas/tendencias , Medios de Comunicación de Masas , Actividades Recreativas/economía , Actividades Recreativas/psicología , Características Culturales , Evolución CulturalRESUMEN
In terms of economics, implementing generic drug policy is nothing other than consolidating (or even, creating) drug markets that set competitive prices, the result of which favors public access to essential drugs. This article approaches the topic of generic drugs from the economic perspective by examining various regulatory models in order to evaluate and leverage generic drug policy implementation options as a mechanism for battling some of the markets specific weaknesses. The conclusion is that there is no single unequivocal method for promoting the use of generic drugs, and that the most favorable way to integrate markets may be through a broad combination of alternatives. These alternatives are grouped and analyzed according to the market issues or challenges that must be overcome. Several options are then identified based on the degree of market consolidation to be obtained.